260 related articles for article (PubMed ID: 29668893)
21. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
Cohen RD; Lewis JR; Turner H; Harrell LE; Hanauer SB; Rubin DT
Inflamm Bowel Dis; 2012 Jan; 18(1):10-6. PubMed ID: 21456032
[TBL] [Abstract][Full Text] [Related]
22. Dose escalation of biologics in Crohn's disease: critical review of observational studies.
Einarson TR; Bereza BG; Ying Lee X; Lelli F
Curr Med Res Opin; 2017 Aug; 33(8):1433-1449. PubMed ID: 28537467
[TBL] [Abstract][Full Text] [Related]
23. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G;
J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637
[TBL] [Abstract][Full Text] [Related]
24. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.
Ricciuto A; Dhaliwal J; Walters TD; Griffiths AM; Church PC
J Crohns Colitis; 2018 Nov; 12(11):1302-1315. PubMed ID: 30107416
[TBL] [Abstract][Full Text] [Related]
25. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
26. Utility of proactive infliximab levels in paediatric Crohn's disease.
Burgess CJ; Reilly C; Steward-Harrison L; Balouch F; Lewindon PJ
Arch Dis Child; 2019 Mar; 104(3):251-255. PubMed ID: 29950353
[TBL] [Abstract][Full Text] [Related]
27. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.
Qiu Y; Chen BL; Mao R; Zhang SH; He Y; Zeng ZR; Ben-Horin S; Chen MH
J Gastroenterol; 2017 May; 52(5):535-554. PubMed ID: 28275925
[TBL] [Abstract][Full Text] [Related]
28. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
Cosnes J; Sokol H; Bourrier A; Nion-Larmurier I; Wisniewski A; Landman C; Marteau P; Beaugerie L; Perez K; Seksik P
Aliment Pharmacol Ther; 2016 Nov; 44(10):1102-1113. PubMed ID: 27666569
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
[TBL] [Abstract][Full Text] [Related]
30. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.
Kopylov U; Al-Taweel T; Yaghoobi M; Nauche B; Bitton A; Lakatos PL; Ben-Horin S; Afif W; Seidman EG
J Crohns Colitis; 2014 Dec; 8(12):1632-41. PubMed ID: 25067824
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
Papamichael K; Cheifetz AS
Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
[TBL] [Abstract][Full Text] [Related]
32. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
Van Steenbergen S; Bian S; Vermeire S; Van Assche G; Gils A; Ferrante M
Aliment Pharmacol Ther; 2017 Apr; 45(7):923-932. PubMed ID: 28164321
[TBL] [Abstract][Full Text] [Related]
33. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Aliment Pharmacol Ther; 2014 Nov; 40(9):1044-55. PubMed ID: 25185992
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea.
Seo H; Ye BD; Song EM; Lee SH; Chang K; Lee HS; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK
Dig Dis Sci; 2017 Oct; 62(10):2882-2893. PubMed ID: 28822006
[TBL] [Abstract][Full Text] [Related]
35. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
Hisamatsu T; Kato S; Kunisaki R; Matsuura M; Nagahori M; Motoya S; Esaki M; Fukata N; Inoue S; Sugaya T; Sakuraba H; Hirai F; Watanabe K; Kanai T; Naganuma M; Nakase H; Suzuki Y; Watanabe M; Hibi T; Nojima M; Matsumoto T;
J Gastroenterol; 2019 Oct; 54(10):860-870. PubMed ID: 31041545
[TBL] [Abstract][Full Text] [Related]
36. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease.
Mattoo VY; Basnayake C; Connell WR; Ding N; Kamm MA; Lust M; Niewiadomski O; Thompson A; Wright EK
Aliment Pharmacol Ther; 2021 Aug; 54(3):249-266. PubMed ID: 34153124
[TBL] [Abstract][Full Text] [Related]
37. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
D'Haens G; Vermeire S; Lambrecht G; Baert F; Bossuyt P; Pariente B; Buisson A; Bouhnik Y; Filippi J; Vander Woude J; Van Hootegem P; Moreau J; Louis E; Franchimont D; De Vos M; Mana F; Peyrin-Biroulet L; Brixi H; Allez M; Caenepeel P; Aubourg A; Oldenburg B; Pierik M; Gils A; Chevret S; Laharie D;
Gastroenterology; 2018 Apr; 154(5):1343-1351.e1. PubMed ID: 29317275
[TBL] [Abstract][Full Text] [Related]
38. Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).
Papamichael K; Jairath V; Zou G; Cohen B; Ritter T; Sands B; Siegel C; Valentine J; Smith M; Vande Casteele N; Dubinsky M; Cheifetz A
BMJ Open; 2022 Apr; 12(4):e057656. PubMed ID: 35365535
[TBL] [Abstract][Full Text] [Related]
39. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.
Yokoyama K; Yamazaki K; Katafuchi M; Ferchichi S
Adv Ther; 2016 Nov; 33(11):1947-1963. PubMed ID: 27664107
[TBL] [Abstract][Full Text] [Related]
40. Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost-effectiveness analysis.
Yao J; Jiang X; You JHS
J Gastroenterol Hepatol; 2021 Sep; 36(9):2397-2407. PubMed ID: 33326123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
